Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $11,175 | $7,453 |
| General and administrative | 3,702 | 2,469 |
| Total operating expenses | 14,877 | 9,922 |
| Loss from operations | (14,877) | (9,922) |
| Interest income and other expense, net | 1,784 | 525 |
| Change in fair value of warrant liability | — | 25,129 |
| Loss before equity method investment | (13,093) | 15,732 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's G&A?
- Corvus Pharmaceuticals (CRVS) reported G&A of $3.7M in Q1 2026.
- How has Corvus Pharmaceuticals's G&A changed year-over-year?
- Corvus Pharmaceuticals's G&A increased by 49.9% year-over-year, from $2.47M to $3.7M.
- What is the long-term trend for Corvus Pharmaceuticals's G&A?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's G&A has grown at a -0.7% compound annual growth rate (CAGR), from $9.52M to $9.25M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Corvus Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude